GENE ONLINE|News &
Opinion
Blog

2022-03-24| Asia-PacificM&A

Fujifilm’s Cell Culture Branch Acquires Recombinant Protein Maker Shenandoah

by Joy Lin
Share To

Fujifilm Irvine Scientific, a cell culture developer and subsidiary of Fujifilm Corporation, is acquiring Shenandoah Biotechnology, a recombinant protein maker based in Pennsylvania. The production of cell and gene therapies have grown rapidly in recent years, fueled by a hotbed of biopharma interest and investment. 

According to Fujifilm, the acquisition of Shenandoah will provide biopharma customers a one-stop shop for their life sciences research, drug discovery, and cell and gene therapy needs. The Shenandoah deal will also help Fujifilm achieve the sales target of $850 million in their Life Sciences Business by 2025, the company said

 

Profile of Shenandoah

 

Founded in 2006, Shenandoah specializes in mass producing recombinant proteins from E. coli. They mainly focus on manufacturing recombinant cytokines, chemokines, and growth factors for research purposes. That includes PDGF, FGF Basic, and TGF beta 1. 

The biotech recently began producing their line of cell therapy grade products from their GMP facility. Shenandoah also provides custom services ranging from inclusion body protein folding and purification, custom protein expression, and bulk protein production.

The companies did not disclose financial details, but the deal is expected to close later this month. 

 

Fujifilm Irvine Scientific Moves to Expand Cell Culture Media Production

 

Fujifilm Irvine Scientific has been busy expanding its manufacturing capacity for cell culture media, its area of specialty. 

Last December, it established a new innovation and collaboration center in Suzhou New District, China, which will focus on upstream cell culture processes for biomanufacturing. The company the same month announced that its manufacturing plant in the Netherlands (and link to European markets) was fully operational. The Dutch facility adds to Fujifilm’s other plants in the US and Japan, increasing the output of its cell culture media products.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Weekly News Highlights: Aug 14-18
2023-08-21
Ginkgo and Boehringer Join Forces in a $406 Million Partnership to Uncover New Therapeutic Molecules
2023-05-11
JPM23: Development and Strategic Updates from JP Morgan Healthcare Conference 2023 Day Two
2023-01-10
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top